A SMAD4-modulated gene profile predicts disease-free survival in stage II and III colorectal cancer

Cancer Rep (Hoboken). 2022 Jan;5(1):e1423. doi: 10.1002/cnr2.1423. Epub 2021 Jun 10.

Abstract

Background: Colorectal cancer is the second-leading cause of cancer-related mortality in the United States and a leading cause of cancer-related mortality worldwide. Loss of SMAD4, a critical tumor suppressor and the central node of the transforming growth factor-beta superfamily, is associated with worse outcomes for colorectal cancer patients; however, it is unknown whether an RNA-based profile associated with SMAD4 expression could be used to better identify high-risk colorectal cancer patients.

Aim: Identify a gene expression-based SMAD4-modulated profile and test its association with patient outcome.

Methods and results: Using a discovery dataset of 250 colorectal cancer patients, we analyzed expression of BMP/Wnt target genes for association with SMAD4 expression. Promoters of the BMP/Wnt genes were interrogated for SMAD-binding elements. Fifteen genes were implicated and three tested for modulation by SMAD4 in patient-derived colorectal cancer tumoroids. Expression of the 15 genes was used for unsupervised hierarchical clustering of a training dataset and two resulting clusters modeled in a centroid model. This model was applied to an independent validation dataset of stage II and III patients. Disease-free survival was analyzed by the Kaplan-Meier method. In vitro analysis of three genes identified in the SMAD4-modulated profile (JAG1, TCF7, and MYC) revealed modulation by SMAD4 consistent with the trend observed in the profile. In the training dataset (n = 553), the profile was not associated with outcome. However, among stage II and III patients (n = 461), distinct clusters were identified by unsupervised hierarchical clustering that were associated with disease-free survival (p = .02, log-rank test). The main model was applied to a validation dataset of stage II/III CRC patients (n = 257) which confirmed the association of clustering with disease-free survival (p = .013, log-rank test).

Conclusions: A SMAD4-modulated gene expression profile identified high-risk stage II and III colorectal cancer patients, can predict disease-free survival, and has prognostic potential for stage II and III colorectal cancer patients.

Keywords: SMAD4; cancer biology; colorectal cancer; gene expression profile; tumor suppressor genes.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Aged
  • Biomarkers, Tumor / genetics
  • Colorectal Neoplasms / genetics*
  • Datasets as Topic
  • Disease-Free Survival
  • Female
  • Gene Expression
  • Genetic Profile*
  • Humans
  • Male
  • Middle Aged
  • Progression-Free Survival
  • Risk Assessment
  • Smad4 Protein / metabolism*

Substances

  • Biomarkers, Tumor
  • SMAD4 protein, human
  • Smad4 Protein